作为一家成立于1986年的老牌中药企业，香雪制药在2010年12月于深交所上市。公司名称取自广州著名景点萝岗香雪。近年来，香雪制药致力于打造从中药 材种植到医药流通的全产业链布局，并开发了包括中药饮片、中成药、医疗器械和T细胞免疫治疗在内的多系列产品。 广州市香雪制药股份有限公司（证券代码：ST香雪，300147.SZ）近期陷入多重困境。根据最新公告，该公司及其子公司在过去一年中涉及的诉讼金额已超 过九千万元。截至2月8日，公司及子公司的诉讼案件累计金额约为9226.56万元，占其最近一期经审计净资产的8.78%。 除了小额案件外，主要的诉讼包括与广州万博佳诚创业投资合作企业之间的合同纠纷，涉案金额达2,092万元，以及与某银行金融借贷纠纷，涉案金额高达 4,496万元。由于部分案件仍在审理或未结案，具体的诉讼影响尚待进一步评估，因此对公司当期及未来的利润影响仍不确定。 公司动态 与此同时，香雪制药在2025年的业绩预告显示，预计全年归母净利润将亏损6.35亿元至9.34亿元，扣非净利润亏损6.12亿元至8.99亿元。造成这一亏损的主要 原因包括市场竞争加剧、流动性危机导致的收入减少和毛利率下降，以及高额的财 ...

公告称，上市公司及子公司涉及的诉讼，鉴于部分案件尚在法院审理中或尚未结案，案件影响金额尚需 进一步评估，诉讼案件对公司本期及期后利润的影响尚无法判断，具体以公司经审计的财务报告为准。 老牌中药企业广州市香雪制药股份有限公司(证券简称：ST香雪（300147），300147.SZ)身陷多重困 境，根据最新披露，上市公司及子公司过去一年涉讼金额超过九千万元。 据ST香雪2月8日公告，截至公告披露日，除已经披露的诉讼事项外，公司及子公司连续十二个月内作 为被告累计涉及的诉讼事项涉案金额合计约9226.56万元，占最近一期经审计净资产8.78%。除几万元至 几十万元的小额案件外，公司与广州万博佳诚创业投资合作企业的合同纠纷涉案金额达到2,092万元， 与中国农业银行股份有限公司化州市支行的金融借贷纠纷涉案金额达到4,496万元。 (经济观察网杜远/文) 上市初期的香雪制药净利润规模一度超过1亿元，但2016年后公司业绩开始下滑。2016年公司净利润同 比下跌超六成，为6602.41万元，2016年—2020年，公司净利润规模保持在6000万元-7000万元规模， 2021年则由盈转亏，当年出现大额亏损6.77亿元。2 ...

Core Viewpoint - ST Xiangxue has been facing significant financial challenges, including ongoing lawsuits and a history of losses, leading to a pre-restructuring process initiated due to its inability to meet debt obligations [1][5][7]. Financial Performance - The company's revenue has declined from over 3 billion yuan in 2020 to over 1.8 billion yuan in 2024 [2]. - The net profit attributable to shareholders has been negative for four consecutive years, with losses of -677 million yuan, -530 million yuan, -389 million yuan, and -859 million yuan from 2021 to 2024 [2]. - The cumulative non-recurring net profit from 2017 to 2024 is approximately -2.511 billion yuan, with only one profitable year in 2020 [2]. 2025 Performance Forecast - For 2025, the company expects a net profit loss between 635 million yuan and 934 million yuan, compared to a loss of 859 million yuan in the previous year [2]. - The anticipated non-recurring net profit loss for 2025 is projected to be between 612 million yuan and 899 million yuan [2]. Factors Affecting Performance - The company faces significant financial burdens, including short-term and long-term borrowings amounting to approximately 250 million yuan in financial expenses [3]. - Fixed asset depreciation and amortization are expected to impact around 200 million yuan [3]. - Asset impairment tests are projected to require approximately 130 million yuan for inventory, construction in progress, fixed assets, and development expenditures [3]. - Legal and overdue interest expenses are estimated to be around 220 million yuan [4]. - Non-recurring gains and losses are expected to influence net profit by about 30 million yuan [5]. Pre-restructuring Process - In January 2025, the company received a notice from creditor Guangdong Jinglong Construction Group, leading to a pre-restructuring application due to its inability to repay debts [5]. - The pre-restructuring period was initially set for three months but has been extended multiple times, with the latest extension to January 11, 2026 [5]. Regulatory Issues - The company has faced administrative penalties for information disclosure violations, resulting in a fine of 6 million yuan and warnings to its actual controller [7]. - The stock was suspended for one day due to these violations and has been placed under risk warnings, changing its name to ST Xiangxue [7]. Market Performance - As of February 6, ST Xiangxue's stock price was 9.50 yuan per share, with a total market capitalization of 6.282 billion yuan [8].

证券代码:300147 证券简称: ST 香雪 公告编号:2026—002 广州市香雪制药股份有限公司 关于累计诉讼事项的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 广州市香雪制药股份有限公司（以下简称"公司"）对公司及子公司连续十 二个月累计涉及诉讼事项进行了统计，现将有关情况公告如下： 一、累计诉讼事项的基本情况 根据《深圳证券交易所股票上市规则（2025 年修订）》的有关规定，上市公 司连续十二个月内发生的诉讼、仲裁事项，涉案金额超过 1,000 万元，且占上市 公司最近一期经审计净资产绝对值 10%以上的，应当及时披露，已经履行披露义 务的，不再纳入累计计算范围。截至本公告披露日，除已经披露的诉讼事项外， 公司及子公司连续十二个月内作为被告累计涉及的诉讼事项涉案金额合计约 9,226.56 万元，占最近一期经审计净资产 8.78%。具体如下： | 原告 | 被告 | 案由 | 进展 | 金额/万元 | | --- | --- | --- | --- | --- | | 广西玉林博康药业有限公司 | 广东化州中药厂制药有限公司、公司 | 合同纠 ...

Market Overview - The Chinese medicine sector experienced a decline of 0.98% on February 2, with Jilin Aodong leading the drop [1] - The Shanghai Composite Index closed at 4015.75, down 2.48%, while the Shenzhen Component Index closed at 13824.35, down 2.69% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Weikang Pharmaceutical (300878) with a closing price of 27.93, up 6.68% [1] - Foci Pharmaceutical (002644) with a closing price of 9.21, up 4.66% [1] - Significant decliners included: - Jilin Aodong (000623) with a closing price of 18.88, down 7.63% [2] - Datang Pharmaceutical (920433) with a closing price of 5.86, down 3.46% [2] Trading Volume and Capital Flow - The Chinese medicine sector saw a net outflow of 235 million yuan from institutional investors, while retail investors contributed a net inflow of approximately 51.97 million yuan [2] - The trading volume for Jilin Aodong reached 504,800 shares, with a transaction value of 977 million yuan [2] Individual Stock Capital Flow - Key capital flows for selected stocks included: - Dong'e Ejiao (000423) with a net inflow of 129 million yuan from institutional investors, but a net outflow of 18.04 million yuan from retail investors [3] - Foci Pharmaceutical (002644) had a net inflow of 43.42 million yuan from institutional investors, with a net outflow of 15.68 million yuan from retail investors [3]

经济观察网2026年1月30日，ST香雪（300147）发布2025年度业绩预告，预计2025年净利润亏损6.35亿 元至9.34亿元。扣除非经常性损益后的净利润亏损6.12亿元至8.99亿元。 ...

证券代码：300147 证券简称：ST 香雪 公告编号：2026-001 广州市香雪制药股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、业绩预计情况 二、与会计师事务所沟通情况 本次业绩预告相关的财务数据为公司财务部门初步测算结果，未经会计师事 务所审计。公司对业绩预告有关事项已与年报审计会计师事务所进行了预沟通， 公司与会计师事务所在本报告期的业绩预告方面不存在分歧。 三、业绩变动原因说明 2025 年，因市场竞争加剧和流动性危机，公司中成药销售不及预期，导致 收入减少和毛利率下降，加之财务费用高、资产负担重及减值准备，同时受预重 整影响，公司净利润仍处于亏损状态。影响公司 2025 年度经营业绩的主要因素 如下： 1、公司存续的短期及长期借款金额较大，财务费用约 25,000 万元。 2、固定资产折旧、摊销影响约 20,000 万元。 3、根据《企业会计准则第 8 号——资产减值》的规定，对合并报表范围内 存在减值迹象的资产进行了减值测试，预计需对存货、在建工程、固定资产、开 发支出等计提资产减值合计约 13,00 ...

Group 1 - The Chinese medicine sector saw a rise of 0.54% on January 20, with *ST Changyao leading the gains [1] - The Shanghai Composite Index closed at 4113.65, down 0.01%, while the Shenzhen Component Index closed at 14155.63, down 0.97% [1] - Notable gainers in the Chinese medicine sector included *ST Changyao with a closing price of 0.53, up 20.45%, and ST Xiangxue with a closing price of 9.72, up 7.05% [1] Group 2 - The Chinese medicine sector experienced a net outflow of 23.25 million yuan from major funds, while retail investors saw a net inflow of 20.95 million yuan [2] - The top stocks by net inflow from retail investors included *ST Changyao and ST Xiangxue, with retail inflows of 2.20 million yuan and 4.16 million yuan respectively [3] - Major funds showed a significant net outflow in stocks like Zhongsheng Pharmaceutical and Yiling Pharmaceutical, with net outflows of 10.68 million yuan and 5.57 million yuan respectively [3]

Market Overview - The Shanghai Composite Index is at 4164.11 points, slightly above the five-day moving average, with a change of -0.03% [1] - The total trading volume of A-shares is 18505.22 billion yuan, with 228 A-shares breaking through the five-day moving average [1] Stocks with Significant Deviation - The stocks with the largest deviation from the five-day moving average include: - Dapeng Industrial (证券代: 920091) with a deviation of 8.06% and a price increase of 10.14% [1] - Hongxing Development (证券代: 600367) with a deviation of 7.42% and a price increase of 10.01% [1] - Prologis Pharmaceutical (证券代: 000739) with a deviation of 7.37% and a price increase of 10.03% [1] Additional Notable Stocks - Other notable stocks with significant price movements include: - Lek Electric (证券代: 603355) with a deviation of 7.20% and a price increase of 9.99% [1] - Tianyi Medical (证券代: 301097) with a deviation of 6.87% and a price increase of 11.59% [1] - Meihu Co., Ltd. (证券代: 603319) with a deviation of 6.30% and a price increase of 7.73% [1] Stocks with Smaller Deviations - Stocks that have just crossed the five-day moving average with smaller deviations include: - Cangge Mining (证券代: 300300) with a deviation of 3.83% and a price increase of 5.01% [1] - ST Xiangxue (证券代: 300147) with a deviation of 3.57% and a price increase of 4.79% [1] - Shandong Molong (证券代: 002490) with a deviation of 3.43% and a price increase of 5.62% [1]

Market Overview - The Chinese medicine sector experienced a decline of 0.32% on December 30, with *ST Changyao leading the drop [1] - The Shanghai Composite Index closed at 3965.12, down 0.0%, while the Shenzhen Component Index closed at 13604.07, up 0.49% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Taiji Group (600129) with a closing price of 18.25, up 2.07% [1] - Wanbangde (002082) at 13.89, up 1.98% [1] - Fangsheng Pharmaceutical (603998) at 11.29, up 1.62% [1] - Conversely, *ST Changyao (300391) saw a significant drop of 19.49%, closing at 0.95 [2] Trading Volume and Value - The trading volume and value for key stocks were as follows: - Taiji Group: 87,200 shares traded, with a transaction value of 159 million [1] - Wanbangde: 164,400 shares traded, with a transaction value of 227 million [1] - Fangsheng Pharmaceutical: 48,000 shares traded, with a transaction value of 53.82 million [1] Capital Flow - The Chinese medicine sector experienced a net outflow of 231 million from institutional investors, while retail investors saw a net inflow of 280 million [2] - The capital flow for specific stocks included: - Wanbangde with a net inflow of 48.79 million from institutional investors [3] - Taiji Group with a net inflow of 18.53 million from institutional investors [3] - *ST Changyao had a net outflow of 19.49% [2]